# Miglustat / OGT 918 in the Treatment of Cystic Fibrosis

> **NCT00537602** · PHASE2 · TERMINATED · sponsor: **Actelion** · enrollment: 6 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** miglustat
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00537602
- **Lead sponsor:** Actelion
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-11
- **Primary completion:** 2008-02
- **Final completion:** 2008-03
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Methodology applied did not meet all criteria required per guidelines
- **Last updated:** 2010-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00537602

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00537602, "Miglustat / OGT 918 in the Treatment of Cystic Fibrosis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00537602. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*